Global Rheumatoid Arthritis Drugs Markets 2018-2022 Featuring Abbvie, Amgen, Bristol-Myers Squibb , F. Hoffmann-La Roche & Pfizer

Global Rheumatoid Arthritis Drugs Markets 2018-2022 Featuring Abbvie, Amgen, Bristol-Myers Squibb , F. Hoffmann-La Roche & Pfizer

DUBLIN, March 21, 2018 /PRNewswire/ --

The "Drugs for Rheumatoid Arthritis: Global Markets to 2022" report has been added to ResearchAndMarkets.com's offering.

http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

This research report categorizes the drugs for rheumatoid arthritis market by type. Product type include disease modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs and corticosteroids.

Report Includes:

    --  95 data tables
    --  An overview of the global rheumatoid arthritis drugs market
    --  Analyses of global market trends, with data from 2016 and 2017, and
        projections of compound annual growth rates (CAGRs) through 2022
    --  Identification of segments with high growth potential and their future
        applications
    --  Explanation of major drivers and regional dynamics of the market and
        current trends within the industry

Key Topics Covered:

1 Introduction

2 Summary and Highlights

3 Drugs for Rheumatoid Arthritis Market Characteristics

4 Drugs for Rheumatoid Arthritis Market Size and Growth

    --  Historic Market Growth
    --  Drivers of the Market
    --  Restraints on the Market
    --  Forecast Market Growth
    --  Drivers of the Market
    --  Restraints on the Market

5 Drugs for Rheumatoid Arthritis Market Trends and Strategies

    --  Increasing Use of Technology
    --  3D Printing Technologies
    --  Combo and Mono Therapy
    --  New Applications of NSAIDS

6 PESTLE Analysis

    --  Political
    --  Government Financial Support
    --  Uncertain Political Policies
    --  Economic
    --  Wealth
    --  Globalization
    --  Emerging Markets
    --  Social
    --  Ageing Global Population
    --  Sedentary Lifestyles
    --  Health Consciousness and Awareness
    --  Traditional Medicine Continues to Pose Threat to Market
    --  Technological
    --  3D Printing Technologies
    --  Internet Penetration and Mobile Applications
    --  Legal
    --  Stringent Regulations and Long Approval Procedures
    --  Investment Regulations
    --  Patent Issues
    --  Government Intervention
    --  Environmental

7 Drugs for Rheumatoid Arthritis Market Segmentation

    --  Global Drugs for Rheumatoid Arthritis Market, By Segment
    --  Global Drugs for Rheumatoid Arthritis Market, Historic and Forecast, By
        Segment, 2013-2022
    --  Disease Modifying Anti-Rheumatic Drugs (DMARDs)
    --  Market Characteristics
    --  Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
    --  Market Characteristics
    --  Corticosteroids
    --  Market Characteristics

8 Drugs for Rheumatoid Arthritis Market Regional and Country Analysis

    --  Global Drugs for Rheumatoid Arthritis Market, By Region
    --  Global Drugs for Rheumatoid Arthritis Market, 2013-2022, Historic and
        Forecast, By Region
    --  Global Drugs for Rheumatoid Arthritis Market Segmentation, By Region,
        2017
    --  Global Drugs for Rheumatoid Arthritis Market, By Country
    --  Global Drugs for Rheumatoid Arthritis Market, Historic and Forecast, By
        Country
    --  Global Drugs for Rheumatoid Arthritis Market Segmentation, 2017, By
        Country

9 Global Drugs for Rheumatoid Arthritis Market Comparison with Macro Economic Factors

    --  Global Per Capita Average Drugs for Rheumatoid Arthritis Market
        Expenditure
    --  Per Capita Average Drugs for Rheumatoid Arthritis Market Expenditure, By
        Country

10 Asia-Pacific Drugs for Rheumatoid Arthritis Market

11 Asia-Pacific Drugs for Rheumatoid Arthritis Market: Country Analysis

12 Western Europe Drugs for Rheumatoid Arthritis Market

13 Western Europe Drugs for Rheumatoid Arthritis Market: Country Analysis

14 Eastern Europe Drugs for Rheumatoid Arthritis Market

15 Eastern Europe Drugs for Rheumatoid Arthritis Market: Country Analysis

16 North America Drugs for Rheumatoid Arthritis Market

17 North America Drugs for Rheumatoid Arthritis Market: Country Analysis18 South America Drugs for Rheumatoid Arthritis Market

19 South America Drugs for Rheumatoid Arthritis Market: Country Analysis

20 Middle East Drugs for Rheumatoid Arthritis Market

21 Africa Drugs for Rheumatoid Arthritis Market

22 Drugs for Rheumatoid Arthritis Market Customer Information

    --  Frequency of Pain after Treatment
    --  Different Symptoms Experienced by Patients
    --  Impact of Rheumatoid Arthritis at Workplace
    --  Importance of Patient's Role in the Management of Rheumatoid Arthritis
    --  Capacity of Affordable Treatment

23 Drugs for Rheumatoid Arthritis Market Competitive Landscape

    --  Company Profiles
    --  Abbvie Inc.
    --  Amgen Inc.
    --  Bristol-Myers Squibb Company
    --  F. Hoffmann-La Roche AG
    --  Pfizer

24 Key Mergers and Acquisitions in the Drugs for Rheumatoid Arthritis Market

    --  Pfizer Acquired Hospira
    --  Concordia Healthcare Acquired Covis Pharma Commercial Assets
    --  Bristol-Myers Squibb Acquired Padlock Therapeutics
    --  Alvotech Acquired Baliopharm
    --  Atnahs Acquired Pharmaceutical Assets of F. Hoffmann-La Roche

25 Appendix

Companies Mentioned

    --  AbbVie Inc.
    --  Amgen Inc.

    --  Biogen
    --  Merck & Co.
    --  Bristol-Myers Squibb
    --  Hoffmann-La Roche
    --  Johnson & Johnson
    --  Mitsubishi Tanabe Pharma Corporation
    --  Pfizer
    --  UCB S.A.

For more information about this report visit https://www.researchandmarkets.com/research/qd8s65/global_rheumatoid?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-rheumatoid-arthritis-drugs-markets-2018-2022-featuring-abbvie-amgen-bristol-myers-squibb--f-hoffmann-la-roche--pfizer-300617394.html

SOURCE Research and Markets